# Alexandria Real Estate Equities

> Alexandria Real Estate Equities is a VC fund backing Biotechnology. See 57 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Pasadena, United States
- Total investments: 57
- Last investment: Jan 2026
- Lead investor: 4%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/alexandria-real-estate-equities-inc.
- Website: http://www.are.com/

Alexandria Real Estate Equities is a VC fund in Pasadena focused on Biotechnology and Health Care. Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry®, is the largest owner and pre-eminent first-in-class real estate investment trust focused principally on science-driven cluster formation. Alexandria is the leading provider of real estate to the life science industry, and has an outstanding 11 year trackrecord as a NYSE listed company with an approximate $5.2 billion total market capitalization (as of December 31, 2008).

## Contacts

5 contacts available for Alexandria Real Estate Equities. Shizune tracks 13 team members at Alexandria Real Estate Equities. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alexandria-real-estate-equities?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 36 | 63% |
| Health Care | 21 | 37% |
| Therapeutics | 15 | 26% |
| Medical | 12 | 21% |
| Pharmaceutical | 10 | 18% |

33 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 18 | 32% |
| Series B | 16 | 28% |
| Series C | 7 | 12% |
| Funding Round | 6 | 11% |
| Series D | 3 | 5% |

8 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John J. Cox | Senior Vice President | 0 | https://shizune.co/investors/profile/john-j-cox |
| Steven Hash | Board of Director | 0 | https://shizune.co/investors/profile/steven-hash |
| Daniel J. Ryan | Executive Vice President | 0 | https://shizune.co/investors/profile/daniel-j-ryan |
| Dean A. Shigenaga | CFO | 0 | https://shizune.co/investors/profile/dean-a-shigenaga |
| Hallie Kuhn | Vice President | 1 | https://shizune.co/investors/profile/hallie-kuhn-7d7b |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mediar Therapeutics | Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M | Series B | Jan 07, 2026 |  |
| TFC Therapeutics | TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer. |  | Seed | Aug 17, 2023 |  |
| TFC Therapeutics | TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer. |  | Pre-Seed | Aug 17, 2023 |  |
| Stablix | Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels andactivity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders. | $63M | Series A | Jun 03, 2021 |  |
| C2i Genomics | C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detecttreatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes.In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York. | $100M | Series B | Apr 15, 2021 |  |
| TerMir | TerMir is an innovative AgTech company that offers pioneering solutions to address key, unresolved agronomic and environmental challenges. | $100K | Grant | Jul 02, 2020 |  |
| Cradle Genomics | At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy. Cradle Genomics is newly formed with theirheadquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus. | $17.1M | Series A | Jul 16, 2019 |  |
| Strand Therapeutics | Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer. | $6M | Seed | Jun 04, 2019 |  |
| Halio | Halio is transforming glass into responsive, intelligent, beautiful architectural elements that transition from clear to tinted to dark – automatically or on command. We're transforming architecture and design by offering a much more versatile architectural element for windows, walls, and skylights.We're transforming buildings andhomes to be more efficient, beautiful, and comfortable.Most importantly, we're transforming lives by giving people unprecedented comfort and control of their indoor environments and more connection to the outside world, while creating inspiring spaces for living and working.We’re doing it through technology. Halio technology is so advanced that we don’t call it electrochromic. Though it does tint when it receives an electrical charge, Halio tints up to 10x faster, it tints uniformly (no more iris or curtain effect), it looks like natural clear glass (no more honey hues), it tints to classic, neutral shades of gray (no more smurf blue), and finally, we give you unlimited tint level options. It's why we thought it needed to be called "smart-tinting glass."​And that’s just the glass itself. Our software and hardware controls are best-of-class – and they’re designed to work seamlessly with building management/automation systems.Beyond performance, our manufacturing techniques result in yields that match the flat panel display industry – and that means on-time deliveries, no matter where in the world your project is located. | $100M | Series D | Jan 30, 2019 |  |
| Avidity Biosciences | Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $16M | Series B | Oct 17, 2018 |  |

10 of 57 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 20 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 11 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 8 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 8 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 8 deals together
- [OVP Venture Partners](https://shizune.co/investors/profile/ovp-venture-partners) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [British Business Investments](https://shizune.co/investors/profile/british-business-investments) — VC Fund
- [White Star Capital](https://shizune.co/investors/profile/white-star-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Venture Capital VC Funds in United States](https://shizune.co/investors/venture-capital-vc-funds-united-states)
- [Venture Capital Investors in United States](https://shizune.co/investors/venture-capital-investors-united-states)
- [Venture Capital VC Funds](https://shizune.co/investors/venture-capital-vc-funds)

## FAQ

### What does Alexandria Real Estate Equities invest in?

Alexandria Real Estate Equities invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alexandria Real Estate Equities?

Public channels for Alexandria Real Estate Equities include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alexandria Real Estate Equities?

The team at Alexandria Real Estate Equities includes John J. Cox (Senior Vice President), Steven Hash (Board of Director) and Daniel J. Ryan (Executive Vice President), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co